Table 2.
Results of clinical evaluation between before and after test granule administration.
| Placebo (n = 54) | ZAZ (n = 56) | |||||
|---|---|---|---|---|---|---|
| Week 0 | Week 1 | Week 13 | Week 0 | Week 1 | Week 13 | |
| UPDRS total score | 46.6 ± 16.3 | 44.7 ± 15.3 | 45.9 ± 18.1 | 46.3 ± 17.1 | 37.1 ± 11.2∗## | 40.7 ± 15.1∗# |
| UPDRS I | 2.5 ± 0.7 | 2.3 ± 1.1 | 2.4 ± 1.2 | 2.6 ± 0.8 | 2.1 ± 0.7* | 2.3 ± 0.9 |
| UPDRS II | 15.7 ± 9.3 | 14.8 ± 11.2 | 15.3 ± 11.6 | 15.9 ± 11.3 | 12.5 ± 4.6∗# | 13.4 ± 9.8∗# |
| UPDRS III | 25.5 ± 12.9 | 23.8 ± 10.6* | 24.9 ± 12.7 | 25.4 ± 10.1 | 19.3 ± 9.8∗# | 21.6 ± 10.4* |
| UPDRS IV | 3.1 ± 1.1 | 2.9 ± 1.6 | 3.0 ± 1.4 | 3.2 ± 1.4 | 2.6 ± 0.8∗# | 2.7 ± 1.3∗# |
| Awake time (counts/min) | 98.5 ± 14.1 | 102.6 ± 18.9 | 100.7 ± 16.9 | 99.8 ± 17.8 | 126.7 ± 13.4∗## | 118.4 ± 11.8∗## |
| Sleep time (counts/min) | 42.9 ± 17.1 | 38.8 ± 15.6* | 40.1 ± 14.8 | 43.2 ± 11.6 | 35.6 ± 13.6∗# | 32.8 ± 13.6∗# |
| α (awake time) | 0.97 ± 0.21 | 0.95 ± 0.28 | 0.96 ± 0.18 | 0.97 ± 0.24 | 0.88 ± 0.21∗# | 0.86 ± 0.19∗## |
| α (sleep-time) | 1.19 ± 0.28 | 1.16 ± 0.27 | 1.15 ± 0.29 | 1.18 ± 0.26 | 1.04 ± 0.22∗# | 1.02 ± 0.18∗## |
Data presented are mean ± SD. *P < .05; **P < .01 compared to week 0 (repeated-measure ANOVAs); #P<.05; ##P < .01 compared to placebo (Bonferroni test); UPDRS: Unified Parkinson's Disease Rating Scale; α: power-law exponent.